Novartis has obtained US Food and Drug Administration (FDA) marketing authorization for ¹⁷⁷Lu-PSMA-617 for metastatic castration-resistant prostate cancer (mCRPC). This new drug is marketed under the name of Pluvicto^TM and is associated with the diagnostic product, ⁶⁸Ga-PSMA-11, under the name of Locametz®. This first marketed radioligand therapy for prostate cancer is a promising news and building hope for prostate cancer patients and a significant event for the radiotheranostics field. This FDA authorization is based on the results of the Phase III VISION trial. Read Press Release >>